Name: RecombiMAb anti-mouse PD-1 (CD279) (D265A)
Brand: CP151
SKU: CP151
Availability: InStock

Skip to the beginning of the images gallery

Technical Data Sheet Safety Data Sheet CoA

Product Details

The RMP1-14-CP151 monoclonal antibody is a chimeric version of the original RMP1-14 antibody. The variable domain sequences are identical to the original RMP1-14 but the constant region sequences have been switched from rat IgG2a to mouse IgG2a. The RMP1-14-CP151 antibody also contains a D265A mutation in the Fc fragment rendering it unable to bind to endogenous Fcγ receptors. RMP1-14-CP151 reacts with mouse PD-1 (programmed death-1) also known as CD279. PD-1 is a 50-55 kDa cell surface receptor encoded by the Pdcd1 gene that belongs to the CD28 family of the Ig superfamily. PD-1 is transiently expressed on CD4 and CD8 thymocytes as well as activated T and B lymphocytes and myeloid cells. PD-1 expression declines after successful elimination of antigen. Additionally, Pdcd1 mRNA is expressed in developing B lymphocytes during the pro-B-cell stage. PD-1’s structure includes a ITIM (immunoreceptor tyrosine-based inhibitory motif) suggesting that PD-1 negatively regulates TCR signals. PD-1 signals via binding its two ligands, PD-L1 and PD-L2 both members of the B7 family. Upon ligand binding, PD-1 signaling inhibits T-cell activation, leading to reduced proliferation, cytokine production, and T-cell death. Additionally, PD-1 is known to play key roles in peripheral tolerance and prevention of autoimmune disease in mice as PD-1 knockout animals show dilated cardiomyopathy, splenomegaly, and loss of peripheral tolerance. Induced PD-L1 expression is common in many tumors including squamous cell carcinoma, colon adenocarcinoma, and breast adenocarcinoma. PD-L1 overexpression results in increased resistance of tumor cells to CD8 T cell mediated lysis. In mouse models of melanoma, tumor growth can be transiently arrested via treatment with antibodies which block the interaction between PD-L1 and its receptor PD-1. For these reasons anti-PD-1 mediated immunotherapies are currently being explored as cancer treatments.

Specifications

Isotype	Mouse IgG2a, κ
Recommended Isotype Control(s)	RecombiMAb mouse IgG2a (D265A) isotype control, anti-hen egg lysozyme
Recommended Dilution Buffer	InVivoPure pH 7.0 Dilution Buffer
Conjugation	This product is unconjugated. Conjugation is available via our Antibody Conjugation Services.
Mutations	D265A
Immunogen	Syrian Hamster BKH cells transfected with mouse PD-1 cDNA
Reported Applications	in vivo blocking of PD-1/PD-L signaling* *Reported for the original rat IgG2a RMP1-14 antibody
Formulation	PBS, pH 7.0 Contains no stabilizers or preservatives
Endotoxin	<1EU/mg (<0.001EU/μg) Determined by LAL gel clotting assay
Aggregation	<5% Determined by SEC
Purity	>95% Determined by SDS-PAGE
Sterility	0.2 µm filtration
Production	Purified from CHO cell supernatant in an animal-free facility
Purification	Protein G
RRID	AB_2927525
Molecular Weight	150 kDa
Murine Pathogen Tests	Ectromelia/Mousepox Virus: Negative Hantavirus: Negative K Virus: Negative Lactate Dehydrogenase-Elevating Virus: Negative Lymphocytic Choriomeningitis virus: Negative Mouse Adenovirus: Negative Mouse Cytomegalovirus: Negative Mouse Hepatitis Virus: Negative Mouse Minute Virus: Negative Mouse Norovirus: Negative Mouse Parvovirus: Negative Mouse Rotavirus: Negative Mycoplasma Pulmonis: Negative Pneumonia Virus of Mice: Negative Polyoma Virus: Negative Reovirus Screen: Negative Sendai Virus: Negative Theiler’s Murine Encephalomyelitis: Negative
Storage	The antibody solution should be stored at the stock concentration at 4°C. Do not freeze.